SA
OCUL icon

Scarborough Advisors’s Ocular Therapeutix OCUL Stock Holding History

Scarborough Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$1.69K – 504
2026
Q1 		$1.69K Buy
+200
New +$1.91K ﹤0.01% 609

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Scarborough Advisors's OCUL Position: Q2 2026 in Review

Scarborough Advisors sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 200 shares — an estimated $1.69K sold.

Scarborough Advisors first reported a position in OCUL in Q1 2026 and held it in 1 quarter. The position peaked at $1.69K in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Scarborough Advisors reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 200 Ocular Therapeutix shares in Q2 2026, an estimated $1.69K.
  • Scarborough Advisors first reported a position in Ocular Therapeutix in Q1 2026 and held it in 1 quarter.
  • Scarborough Advisors's Ocular Therapeutix position peaked at $1.69K in Q1 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.